Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* CKD (stage V) on outpatient hemodialysis therapy for \>= 3 months;~* CKD-related anemia treated with epoetin alfa iv 3x/week for \>= 3 months;~* average hemoglobin (Hb) 10-12 g/dL over last 3 months.~Exclusion Criteria:~* failed renal transplant within 12 months prior to screening;~* poorly controlled hypertension;~* previous treatment with Mircera.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- methoxy polyethylene glycol-epoetin beta (Type: EXPERIMENTAL): 120-360 micrograms (iv) monthly, starting dose
- Epoetin Alfa (Type: ACTIVE_COMPARATOR): As prescribed, (iv), 3 times weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).